041960 — Komipharm International Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapHigh Flyer

Annual income statement for Komipharm International Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	37,160	35,847	39,801	42,647	58,779
Cost of Revenue
Gross Profit	13,376	11,234	11,459	12,658	21,764
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	40,033	41,489	43,790	49,018	53,821
Operating Profit	-2,873	-5,642	-3,990	-6,371	4,957
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,957	-5,934	-7,480	-5,739	14,690
Provision for Income Taxes
Net Income After Taxes	-3,957	-5,934	-7,480	-5,911	14,690
Minority Interest
Net Income Before Extraordinary Items
Net Income	-2,816	-4,459	-6,514	-3,979	13,113
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-2,816	-4,459	-6,514	-3,979	13,113
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-32.2	-58.4	-90	-56.4	75.7
Dividends per Share